Work

978P Pertuzumab plus trastuzumab (P+T) in patients (pts) with lung cancer (LC) with ERBB2 mutation (mut) or amplification (amp): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study

Year: 2022

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2022.07.1106

Authors: A.K. Ganti, M. Rothe, P.K. Mangat, E. Garrett-Mayer, E.G. Dib, H. Duvivier, E. Ahn, D. Behl, H. Borghaei, A.S. Balmanoukian, A. Gaba, R. Li, K. Osei-Boateng, R. Thota, R. O'Lone, G.N. Grantham, S. Halabi, R.L. Schilsky

Institutions: University of Nebraska Medical Center, American Society of Clinical Oncology, Michigan Cancer Research Consortium, Cancer Treatment Centers of America, Sutter Institute for Medical Research, Fox Chase Cancer Center, Angeles Clinic and Research Institute, Sanford Health, Sanford Medical Center, Providence Portland Medical Center, Levine Cancer Institute, Intermountain Healthcare, Intermountain Medical Center, Duke University Health System

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Merck, American Society of Clinical Oncology, University of Nebraska Medical Center, BeiGene, Incyte, Natera, Genentech, Merck Sharp and Dohme

OpenAlex ID: W4295816689

FWCI: 0.162

Cites:

Cited by: 1

Related to: 10